{
  "pmid": "41570741",
  "title": "ALS-related proteinopathies: From TDP-43 to mitochondrial proteinopathies.",
  "abstract": "Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by the progressive loss of motor neurons. ALS often overlaps clinically and pathologically with frontotemporal dementia (FTD), the second most common form of dementia. Like many neurodegenerative disorders, both ALS and FTD share a crucial pathological hallmark, the aggregation of misfolded proteins into insoluble inclusions in degenerating neurons. This process is referred to as proteinopathy. This review focuses on the proteinopathies associated with ALS, including aggregates of TDP-43, SOD1, FUS, and CHCHD10, which disrupt critical cellular processes such as RNA metabolism, mitochondrial function, and protein homeostasis. The review highlights to the identification of new types of mitochondrial and cytosolic aggregates linked to CHCHD10-related ALS. Although the precise pathological mechanisms remain to be fully elucidated, strategies aimed at restoring proteostasis and reducing protein aggregation may be promising therapeutic approaches for treating ALS, as they directly target fundamental pathogenic mechanisms.",
  "journal": "Current opinion in neurobiology",
  "year": "2026",
  "authors": [
    {
      "lastName": "Genin",
      "foreName": "Emmanuelle C",
      "initials": "EC",
      "affiliation": ""
    },
    {
      "lastName": "Paquis-Flucklinger",
      "foreName": "VÃ©ronique",
      "initials": "V",
      "affiliation": ""
    }
  ],
  "keywords": [],
  "doi": "10.1016/j.conb.2025.103163",
  "pmcId": null,
  "meshTerms": [],
  "rawXml": "<?xml version=\"1.0\" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2025//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd\">\n<PubmedArticleSet>\n<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\"><PMID Version=\"1\">41570741</PMID><DateRevised><Year>2026</Year><Month>01</Month><Day>22</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1873-6882</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>97</Volume><PubDate><Year>2026</Year><Month>Jan</Month><Day>21</Day></PubDate></JournalIssue><Title>Current opinion in neurobiology</Title><ISOAbbreviation>Curr Opin Neurobiol</ISOAbbreviation></Journal><ArticleTitle>ALS-related proteinopathies: From TDP-43 to mitochondrial proteinopathies.</ArticleTitle><Pagination><StartPage>103163</StartPage><MedlinePgn>103163</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1016/j.conb.2025.103163</ELocationID><ELocationID EIdType=\"pii\" ValidYN=\"Y\">S0959-4388(25)00194-1</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by the progressive loss of motor neurons. ALS often overlaps clinically and pathologically with frontotemporal dementia (FTD), the second most common form of dementia. Like many neurodegenerative disorders, both ALS and FTD share a crucial pathological hallmark, the aggregation of misfolded proteins into insoluble inclusions in degenerating neurons. This process is referred to as proteinopathy. This review focuses on the proteinopathies associated with ALS, including aggregates of TDP-43, SOD1, FUS, and CHCHD10, which disrupt critical cellular processes such as RNA metabolism, mitochondrial function, and protein homeostasis. The review highlights to the identification of new types of mitochondrial and cytosolic aggregates linked to CHCHD10-related ALS. Although the precise pathological mechanisms remain to be fully elucidated, strategies aimed at restoring proteostasis and reducing protein aggregation may be promising therapeutic approaches for treating ALS, as they directly target fundamental pathogenic mechanisms.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Genin</LastName><ForeName>Emmanuelle C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Universit&#xe9; C&#xf4;te d'Azur (UniCA), Inserm U1081, CNRS UMR7284, Institute for Research on Cancer and Aging, Nice (IRCAN), Team &#xab;Mitochondria, diseases and Aging&#xbb;, Nice, France. Electronic address: emmanuelle.genin@univ-cotedazur.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Paquis-Flucklinger</LastName><ForeName>V&#xe9;ronique</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Universit&#xe9; C&#xf4;te d'Azur (UniCA), Inserm U1081, CNRS UMR7284, Institute for Research on Cancer and Aging, Nice (IRCAN), Team &#xab;Mitochondria, diseases and Aging&#xbb;, Nice, France; Department of Medical Genetics &amp; Reference Centre for Mitochondrial Disease, Nice Universitary Hospital, Nice, France. Electronic address: paquis@unice.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D016454\">Review</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2026</Year><Month>01</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Opin Neurobiol</MedlineTA><NlmUniqueID>9111376</NlmUniqueID><ISSNLinking>0959-4388</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2025</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2025</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2025</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2026</Year><Month>1</Month><Day>23</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2026</Year><Month>1</Month><Day>23</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2026</Year><Month>1</Month><Day>22</Day><Hour>18</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">41570741</ArticleId><ArticleId IdType=\"doi\">10.1016/j.conb.2025.103163</ArticleId><ArticleId IdType=\"pii\">S0959-4388(25)00194-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>",
  "fetched_at": "2026-01-29T19:53:40.571Z"
}